Leukemia Treatment Advances with FDA Approval of Blincyto by Amgen for B-ALL
Leukemia treatment has advanced with the Food and Drug Administration's (FDA) approval of Amgen’s Blincyto (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic...
FDA Approves Amgen’s IMDELLTRA™ for Lung Cancer, Offering New Hope for Patients
Amgen's groundbreaking IMDELLTRA™ (tarlatamab-dlle) therapy has received the Food and Drug Administration (FDA) approval for the treatment of extensive-stage small cell lung cancer (ES-SCLC)...
Competition Heats Up for First-Line KRAS Inhibitor in Lung Cancer Treatment
In the relentless quest to combat KRAS-mutated non-small cell lung cancer (NSCLC), Amgen's Lumakras and Mirati's Krazati have secured approval for second-line treatment. However,...
